Medicines

Drugging the undruggable? KRAS inhibitor shows early promise

Selective inhibition of the KRAS p.G12C mutation is offering some promise for patients with locally advanced and metastatic solid tumours. A phase 1 trial of sotorasib in 129 patients - including Australians - with mainly non-small cell lung cancer (NSCLC) and...

Selective inhibition of the KRAS p.G12C mutation is offering some promise for patients with locally advanced and metastatic solid tumours. A...
Breast cancer

New first-in-class treatment option for triple negative breast cancer

Sacituzumab govitecan should become the new standard of care in women with previously treated metastatic triple-negative breast cancer (mTNBC), according to discussion at ESMO 2020. A phase 3 study, presented at the ESMO Virtual Congress 2020, randomised 529 women to either...

Sacituzumab govitecan should become the new standard of care in women with previously treated metastatic triple-negative breast cancer (mTNBC), according...